AzTrials
AzTrials

Nursing CariesNCT05665868

Study on Integrated Nursing Strategy for Patients With Gastrointestinal Stromal Tumors After Targeted Therapy

A study testing integrated care mode and conventional care mode in people with Nursing Caries and Gastrointestinal Stromal Tumors, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to construct a symptom management strategy for patients with gastrointestinal stromal tumor targeted therapy based on symptom management theory under the guidance of MRC framework. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
integrated care mode and conventional care mode
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
62 participants
Where
1 siteChina
Study dates
1 Apr 2022to 1 Apr 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients diagnosed as gastrointestinal stromal tumor and receiving targeted therapy
  • Over 18 years old, with normal communication ability
  • Will use smart phones, or the family members who will use smart phones will live in the meeting
  • Informed consent and voluntary participation in this study.

Who cannot join

  • Patients with psychiatric history or congenital mental retardation
  • The patient or his/her cohabiting family members cannot complete the health status self test, health status assessment and questionnaire under the prompts of the platform.
  • Criteria for case termination:
  • Those who voluntarily put forward termination during the study period and are unwilling to accept follow-up or refuse to fill in the questionnaire
  • Death
  • Lost subjects

Trial locations and contacts

1 site in 1 country.

Li Chen, Bachelor contact

(+86)13770336619

chenligulou@163.com

Zhijian Liu, Doctor contact

(+86)15951814859

njulzj@126.com

China1 site, 1 recruiting
  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, 210000

    Li Chen, Bachelor, (+86)13770336619, chenligulou@163.com

    Recruiting

Other trials in China

About this study

Official title: The Construction and Empirical Study of Symptom Management and Integrated Care Strategy for Gastrointestinal Stromal Tumor Patients With Targeted Therapy Based on MRC Framework

The goal of this clinical trial is to construct a symptom management strategy for patients with gastrointestinal stromal tumor targeted therapy based on symptom management theory under the guidance of MRC framework. Embed the symptom management strategy into the information platform and conduct an empirical study on integrated care for GIST patients, and compare it with the traditional outpatient follow-up patients to explore the safety and effectiveness of the symptom management strategy and the application effect of the integrated care platform.

Read the detailed description

The purpose of this clinical trial is to build an information platform for symptom management and integrated care strategy of gastrointestinal stromal tumor targeted treatment patients: the system is composed of big data platform and care strategy platform. The big data platform can automatically extract patient data from HIS, Medcare and other patient diagnosis and treatment systems according to the pre-set patient inclusion criteria, form a health file of gastrointestinal stromal tumor targeted treatment patients, and complete the enrollment. The system will intelligently promote the care strategies of the patients included in the big data platform, promote the two-way communication between doctors and patients, and realize the functions of timed symptom evaluation, symptom management, symptom management result feedback, etc. All patient health data can be customized output through the big data platform. The two platforms complement each other, promote patient self-management, improve the quality of medical follow-up service, reduce the workload of medical personnel, optimize the use of medical resources, and improve the quality of scientific research data. It is not necessary for patients to judge how to take intervention measures, but the system's management center decision-making module will evaluate the symptoms of patients, and then pop up corresponding measures, so that patients can more effectively cope with the discomfort of related symptoms caused by targeted treatment at home, and alleviate the impact on life.

Being tested
integrated care mode, conventional care mode
Medical subject headings
Gastrointestinal Stromal Tumors

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • integrated care modeDevice

    The information system consists of big data platform and nursing strategy platform. The system includes medical work end, patient operation end and administrator management end. The big data platform can automatically extract patient data from HIS, Medcare and other patient diagnosis and treatment systems, complete registration and establish patient health files according to the preset patient registration standards. By comparing the data input on the patient side with the database set on the platform, the system decision-making module can generate personalized measures and plans for feedback to patients, and can generate patient information overview feedback to the nurse side. Complete intelligent push of symptom management decision model

  • conventional care modeDevice

    ① The health education manual for patients receiving targeted treatment of gastric stromal tumors will be issued. The patients who need targeted treatment will be identified and followed up in the routine outpatient department (1 month, 3 months, 6 months, 12 months after surgery, and once a year thereafter); ② Telephone follow-up (1 month, 3 months, 6 months, 12 months and once a year thereafter); ③ Patients independently complete disease symptom monitoring, lifestyle adjustment, and other disease self-management.

Study groups in NCT05665868
Study groupRoleWhat they receive
Experimental group based on integrated care modeExperimental① Obtain the health records of patients receiving targeted treatment of gastric stromal tumors in the big data platform; ② Patients upload health data, disease symptoms, complete questionnaires, health consultation and other functions; ③ The platform can regularly send audit reminders, automatically analyze the data uploaded and saved by patients, automatically and intelligently intervene when abnormal results occur, and remind medical staff to intervene manually; ④ Researchers can view the recent health status of patients through the terminal, and members of corresponding disciplines can give targeted health guidance according to the existing health problems of patients; Remind patients with complex conditions to have outpatient reexamination; ⑤ Push disease related knowledge every week for patients to learn independently.
Receives: Device: integrated care mode
Control group based on conventional care modeActive comparator① The health education manual for patients receiving targeted treatment of gastric stromal tumors will be issued. The patients who need targeted treatment will be identified and followed up in the routine outpatient department (1 month, 3 months, 6 months, 12 months after surgery, and once a year thereafter); ② Telephone follow-up (1 month, 3 months, 6 months, 12 months and once a year thereafter); ③ Patients independently complete disease symptom monitoring, lifestyle adjustment, and other disease self-management.
Receives: Device: conventional care mode

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Scoring of quality of life using the cancer treatment function evaluation system

    Evaluate the quality of life of patients. The scale consists of 27 items: 7 items of physiological status (coded GP1-GP7), 7 items of social/family status (GS1-GS7), 6 items of emotional status (GE1-GE6) and 7 items of functional status (GF1-GF7). Each item adopts a 5-level scoring method. From "not at all" to "very", the score is 0-4, respectively. Among them, GP1-GP7, GE1, and GE3-GE6 are reverse items.

    Measured: One month after intervention

  2. Scoring of quality of life using the cancer treatment function evaluation system

    Evaluate the quality of life of patients. The scale consists of 27 items: 7 items of physiological status (coded GP1-GP7), 7 items of social/family status (GS1-GS7), 6 items of emotional status (GE1-GE6) and 7 items of functional status (GF1-GF7). Each item adopts a 5-level scoring method. From "not at all" to "very", the score is 0-4, respectively. Among them, GP1-GP7, GE1, and GE3-GE6 are reverse items.

    Measured: Three month after intervention

  3. Scoring of quality of life using the cancer treatment function evaluation system

    Evaluate the quality of life of patients. The scale consists of 27 items: 7 items of physiological status (coded GP1-GP7), 7 items of social/family status (GS1-GS7), 6 items of emotional status (GE1-GE6) and 7 items of functional status (GF1-GF7). Each item adopts a 5-level scoring method. From "not at all" to "very", the score is 0-4, respectively. Among them, GP1-GP7, GE1, and GE3-GE6 are reverse items.

    Measured: Six month after intervention

  4. Quality of life score of patients assessed by the specific module of gastric cancer of Anderson Symptom Assessment Scale

    It is widely applicable to cancer patients of different types and treatments. The scale consists of two parts, which measure the severity of 13 core cancer symptoms and "symptom interference", that is, the interference of symptoms to patients and the specific module of gastrointestinal cancer. The severity of 13 core symptoms was evaluated for cancer symptoms, including pain, fatigue, nausea, restless sleep, distress, shortness of breath, amnesia, anorexia, drowsiness, dry mouth, sadness, vomiting and numbness, of which 2 items evaluated sleep problems; Symptom interference assessment The interference degree of the above 13 core symptoms to the six daily life items of general activities, work, emotion, walking, interpersonal relationship and fun of life. Each item is scored from 0 to 10 points, 0-4 points are mild, 5-6 points are moderate, and ≥ 7 points are severe.

    Measured: One month after intervention

  5. Quality of life score of patients assessed by the specific module of gastric cancer of Anderson Symptom Assessment Scale

    It is widely applicable to cancer patients of different types and treatments. The scale consists of two parts, which measure the severity of 13 core cancer symptoms and "symptom interference", that is, the interference of symptoms to patients and the specific module of gastrointestinal cancer. The severity of 13 core symptoms was evaluated for cancer symptoms, including pain, fatigue, nausea, restless sleep, distress, shortness of breath, amnesia, anorexia, drowsiness, dry mouth, sadness, vomiting and numbness, of which 2 items evaluated sleep problems; Symptom interference assessment The interference degree of the above 13 core symptoms to the six daily life items of general activities, work, emotion, walking, interpersonal relationship and fun of life. Each item is scored from 0 to 10 points, 0-4 points are mild, 5-6 points are moderate, and ≥ 7 points are severe.

    Measured: Three month after intervention

  6. Quality of life score of patients assessed by the specific module of gastric cancer of Anderson Symptom Assessment Scale

    It is widely applicable to cancer patients of different types and treatments. The scale consists of two parts, which measure the severity of 13 core cancer symptoms and "symptom interference", that is, the interference of symptoms to patients and the specific module of gastrointestinal cancer. The severity of 13 core symptoms was evaluated for cancer symptoms, including pain, fatigue, nausea, restless sleep, distress, shortness of breath, amnesia, anorexia, drowsiness, dry mouth, sadness, vomiting and numbness, of which 2 items evaluated sleep problems; Symptom interference assessment The interference degree of the above 13 core symptoms to the six daily life items of general activities, work, emotion, walking, interpersonal relationship and fun of life. Each item is scored from 0 to 10 points, 0-4 points are mild, 5-6 points are moderate, and ≥ 7 points are severe.

    Measured: Six month after intervention

  7. Anxiety tendency of patients in the past week assessed by self rating anxiety scale

    It can accurately evaluate the anxiety tendency of patients in the past week. The evaluation method is convenient and highly operable. The evaluation time is short and the content is easy to understand. Cronbach's of SAS α The coefficient is 0.824, including 20 items, with a total score of 100 points. In the entry, "1 minute" means no or very little time, "2 minutes" means a small part of time, and "3 minutes" means a considerable amount of time; "4 points" means most or all of the time, in which items 5, 9, 13, 17 and 19 are scored reversely. The integral part of the original score multiplied by 1.25 is the final standard score. The higher the total score, the more obvious the anxiety symptoms of the patient. The score of normal emotion is below 50, the score of mild anxiety is between 50-59, the score of moderate anxiety is between 60-69, and the score of more than 70 is severe anxiety.

    Measured: One month after intervention

  8. Anxiety tendency of patients in the past week assessed by self rating anxiety scale

    It can accurately evaluate the anxiety tendency of patients in the past week. The evaluation method is convenient and highly operable. The evaluation time is short and the content is easy to understand. Cronbach's of SAS α The coefficient is 0.824, including 20 items, with a total score of 100 points. In the entry, "1 minute" means no or very little time, "2 minutes" means a small part of time, and "3 minutes" means a considerable amount of time; "4 points" means most or all of the time, in which items 5, 9, 13, 17 and 19 are scored reversely. The integral part of the original score multiplied by 1.25 is the final standard score. The higher the total score, the more obvious the anxiety symptoms of the patient. The score of normal emotion is below 50, the score of mild anxiety is between 50-59, the score of moderate anxiety is between 60-69, and the score of more than 70 is severe anxiety.

    Measured: Three month after intervention

  9. Anxiety tendency of patients in the past week assessed by self rating anxiety scale

    It can accurately evaluate the anxiety tendency of patients in the past week. The evaluation method is convenient and highly operable. The evaluation time is short and the content is easy to understand. Cronbach's of SAS α The coefficient is 0.824, including 20 items, with a total score of 100 points. In the entry, "1 minute" means no or very little time, "2 minutes" means a small part of time, and "3 minutes" means a considerable amount of time; "4 points" means most or all of the time, in which items 5, 9, 13, 17 and 19 are scored reversely. The integral part of the original score multiplied by 1.25 is the final standard score. The higher the total score, the more obvious the anxiety symptoms of the patient. The score of normal emotion is below 50, the score of mild anxiety is between 50-59, the score of moderate anxiety is between 60-69, and the score of more than 70 is severe anxiety.

    Measured: Six month after intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Dec 2022
  2. Study start1 Apr 2022
  3. Primary completion1 Jun 2023 (estimated)
  4. Study completion1 Apr 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
62 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05665868
Sponsor's protocol ID
2022-LCYJ-MS-30
Status last verified
Nov 2022
First submitted
27 Nov 2022
Last updated
27 Dec 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing integrated care mode and conventional care mode in people with Nursing Caries and Gastrointestinal Stromal Tumors, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 27 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Li Chen, Bachelor ((+86)13770336619, chenligulou@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Scoring of quality of life using the cancer treatment function evaluation system (time frame: One month after intervention). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Dec 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in